mitoxantrone has been researched along with Malignant Melanoma in 33 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Melphalan administered by isolated hyperthermic perfusion of the affected limb is an accepted treatment for malignant melanoma of the extremities." | 9.08 | Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb. ( Huber, PM; Huber, R; Krüger, I; Kuper, K; Pichlmaier, H, 1995) |
| " In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP)." | 8.12 | Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Marzęda, P; Wróblewska-Łuczka, P; Załuska-Ogryzek, K; Łuszczki, JJ, 2022) |
| " The aim of this study was to investigate the cytotoxic and anti-proliferative effects of arvanil and olvanil when administered alone and in combination with cisplatin (CDDP) and mitoxantrone (MTX), using various primary (A375, FM55P) and metastatic (SK-MEL 28, FM55M2) human malignant melanoma cell lines." | 8.12 | Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Góralczyk, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "This study evaluated the effects of mitoxantrone (MX), an antitumor agent, as a sensitizer to both photodynamic and radiation therapy in DFW human melanoma cells." | 7.79 | Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. ( Ahmadi, A; Bahreyni-Toosi, MH; Montazerabadi, AR; Sazgarnia, A, 2013) |
| "Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week)." | 7.67 | Mitoxantrone in malignant melanoma. ( Bartolucci, A; Gams, R; Presant, CA, 1984) |
| "The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of Dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in 28 patients with advanced malignant melanoma, none of whom had received prior cytotoxic chemotherapy." | 7.67 | A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma. ( Arseneau, JC; Borden, EC; Schoenfeld, DA, 1986) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 7.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "(1) Malignant melanomas are dangerous skin cancers, and the treatment of melanomas with various cytostatic drugs often causes side effects and after their prolonged use resistance to these drugs appears." | 5.91 | Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ, 2023) |
| "Malignant melanoma is a skin cancer characterized by rapid development, poor prognosis and high mortality." | 5.72 | Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Grabarska, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "Mitoxantrone (MTO) was topically applied for melanoma therapy using an MTO ethosome gel." | 5.42 | Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel. ( Du, L; Fu, G; Jin, Y; Li, Y; Yu, X, 2015) |
| "Anacardic acid is a potent epigenetic agent with anticancer activity." | 5.40 | Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies. ( Filipczak, N; Gubernator, J; Kozubek, A; Legut, M; Lipka, D; Piwoni, A, 2014) |
| " In this in vitro study we tried to reveal the anticancer properties of CBD in malignant melanoma cell lines (SK-MEL 28, A375, FM55P and FM55M2) administered alone, as well as in combination with mitoxantrone (MTX) or cisplatin (CDDP)." | 4.12 | Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Marzęda, P; Wróblewska-Łuczka, P; Załuska-Ogryzek, K; Łuszczki, JJ, 2022) |
| " The aim of this study was to investigate the cytotoxic and anti-proliferative effects of arvanil and olvanil when administered alone and in combination with cisplatin (CDDP) and mitoxantrone (MTX), using various primary (A375, FM55P) and metastatic (SK-MEL 28, FM55M2) human malignant melanoma cell lines." | 4.12 | Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis. ( Drozd, M; Florek-Łuszczki, M; Góralczyk, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| "This study evaluated the effects of mitoxantrone (MX), an antitumor agent, as a sensitizer to both photodynamic and radiation therapy in DFW human melanoma cells." | 3.79 | Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells. ( Ahmadi, A; Bahreyni-Toosi, MH; Montazerabadi, AR; Sazgarnia, A, 2013) |
| "Transdermal delivery of mitoxantrone liposomes could be a potential therapy for cutaneous malignant melanoma." | 3.73 | [Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery]. ( Chen, T; Hou, SX; Sun, YY; Zheng, Y, 2006) |
| "The clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg were studied in five patients exhibiting solitary, localized malignant melanoma." | 3.68 | Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg. ( Bode, U; Ghussen, F; Krüger, I; Nagel, JD, 1991) |
| "Twenty-nine patients with metastatic malignant melanoma without prior chemotherapy and 36 patients refractory to prior chemotherapy received mitoxantrone (5 mg/m2/week)." | 3.67 | Mitoxantrone in malignant melanoma. ( Bartolucci, A; Gams, R; Presant, CA, 1984) |
| "In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks." | 3.67 | Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene. ( Bishop, J; Coates, AS; Mann, GJ; Raghavan, D, 1986) |
| "Mitoxantrone, an anthracenedione derivative, was administered by members of the Southwest Oncology Group to thirty patients with metastatic malignant melanoma." | 3.67 | Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot. ( Costanzi, JJ; Taylor, SA; Tranum, BT; Von Hoff, DD, 1985) |
| "(1) Malignant melanomas are dangerous skin cancers, and the treatment of melanomas with various cytostatic drugs often causes side effects and after their prolonged use resistance to these drugs appears." | 1.91 | Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Wróblewska-Łuczka, P; Łuszczki, JJ, 2023) |
| "Malignant melanoma is a skin cancer characterized by rapid development, poor prognosis and high mortality." | 1.72 | Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis. ( Góralczyk, A; Grabarska, A; Marzęda, P; Wróblewska-Łuczka, P; Łuszczki, JJ, 2022) |
| " The affected tumors remained dormant long after dosing stopped, resulting in a prolonged progression-free survival and sustained immune surveillance of the host bearing desmoplastic melanoma." | 1.48 | Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma. ( Chen, F; Hou, L; Huang, L; Liu, Q; Shen, L; Wang, D; Zhang, X, 2018) |
| "Mitoxantrone (MTO) was topically applied for melanoma therapy using an MTO ethosome gel." | 1.42 | Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel. ( Du, L; Fu, G; Jin, Y; Li, Y; Yu, X, 2015) |
| "Anacardic acid is a potent epigenetic agent with anticancer activity." | 1.40 | Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies. ( Filipczak, N; Gubernator, J; Kozubek, A; Legut, M; Lipka, D; Piwoni, A, 2014) |
| "Mitoxantrone has not gained widespread acceptance in the veterinary community, primarily due to its cost and single-dose packaging in a volume that exceeds the needs of the majority of veterinary cancer patients." | 1.31 | Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles. ( Mauldin, GN; Truax, R, 2002) |
| "Choroidal melanoma has a high mortality rate and responds poorly to existing chemotherapy, but unexpected ex vivo sensitivity of a subset of these tumours to topoisomerase II inhibitors has been noted." | 1.31 | Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma. ( Alexander, RA; Cree, IA; de Souza, L; Foss, AJ; Hickson, ID; Hungerford, JL; Myatt, N; Neale, MH; Satherley, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (33.33) | 18.7374 |
| 1990's | 3 (9.09) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 9 (27.27) | 24.3611 |
| 2020's | 7 (21.21) | 2.80 |
| Authors | Studies |
|---|---|
| Zee-Cheng, RK | 3 |
| Podrebarac, EG | 1 |
| Menon, CS | 1 |
| Cheng, CC | 3 |
| Mathew, AE | 1 |
| Xu, PL | 1 |
| Northcutt, RV | 1 |
| Marzęda, P | 5 |
| Wróblewska-Łuczka, P | 7 |
| Drozd, M | 4 |
| Florek-Łuszczki, M | 4 |
| Załuska-Ogryzek, K | 1 |
| Łuszczki, JJ | 7 |
| Góralczyk, A | 6 |
| Grabarska, A | 1 |
| Pfeifer, V | 1 |
| Weber, H | 1 |
| Wang, Y | 1 |
| Schlesinger, M | 1 |
| Gorzelanny, C | 1 |
| Bendas, G | 1 |
| Liu, H | 1 |
| Kuang, X | 1 |
| Zhang, Y | 1 |
| Ye, Y | 1 |
| Li, J | 1 |
| Liang, L | 1 |
| Xie, Z | 1 |
| Weng, L | 1 |
| Guo, J | 1 |
| Li, H | 1 |
| Ma, F | 1 |
| Chen, X | 2 |
| Zhao, S | 1 |
| Su, J | 1 |
| Yang, N | 1 |
| Fang, F | 1 |
| Xie, Y | 1 |
| Tao, J | 1 |
| Zhang, J | 1 |
| Chen, M | 1 |
| Peng, C | 1 |
| Sun, L | 1 |
| Zhang, X | 2 |
| Liu, J | 1 |
| Han, L | 1 |
| Xu, X | 1 |
| Hung, MC | 1 |
| Liu, Q | 1 |
| Chen, F | 1 |
| Hou, L | 1 |
| Shen, L | 1 |
| Wang, D | 1 |
| Huang, L | 1 |
| Imanparast, A | 1 |
| Bakhshizadeh, M | 2 |
| Salek, R | 1 |
| Sazgarnia, A | 3 |
| Mohajeri, SA | 1 |
| Esmaily, H | 1 |
| Aledavood, SA | 1 |
| Varshoei Tabrizi, F | 1 |
| Seifi, M | 1 |
| Hadizadeh, F | 1 |
| Legut, M | 1 |
| Lipka, D | 1 |
| Filipczak, N | 1 |
| Piwoni, A | 1 |
| Kozubek, A | 1 |
| Gubernator, J | 1 |
| Yu, X | 2 |
| Du, L | 2 |
| Zhu, L | 1 |
| Liu, X | 1 |
| Zhang, B | 1 |
| Fu, G | 2 |
| Jin, Y | 2 |
| Li, Z | 1 |
| Zhang, FL | 1 |
| Pan, LL | 1 |
| Zhu, XL | 1 |
| Zhang, ZZ | 1 |
| Li, Y | 1 |
| Spugnini, EP | 1 |
| Fanciulli, M | 1 |
| Citro, G | 1 |
| Baldi, A | 1 |
| Montazerabadi, AR | 1 |
| Bahreyni-Toosi, MH | 1 |
| Ahmadi, A | 1 |
| Mauldin, GN | 1 |
| Truax, R | 1 |
| Chen, T | 1 |
| Hou, SX | 1 |
| Sun, YY | 1 |
| Zheng, Y | 1 |
| Alberts, DS | 1 |
| Peng, YM | 1 |
| Leigh, S | 1 |
| Davis, TP | 1 |
| Woodward, DL | 1 |
| Presant, CA | 1 |
| Gams, R | 1 |
| Bartolucci, A | 1 |
| Fujimoto, S | 1 |
| Ogawa, M | 1 |
| Huber, R | 1 |
| Krüger, I | 2 |
| Kuper, K | 1 |
| Huber, PM | 1 |
| Pichlmaier, H | 1 |
| Kirshenbaum, MR | 1 |
| Chen, SF | 1 |
| Behrens, CH | 1 |
| Papp, LM | 1 |
| Stafford, MM | 1 |
| Sun, JH | 1 |
| Behrens, DL | 1 |
| Fredericks, JR | 1 |
| Polkus, ST | 1 |
| Sipple, P | 1 |
| Satherley, K | 1 |
| de Souza, L | 1 |
| Neale, MH | 1 |
| Alexander, RA | 1 |
| Myatt, N | 1 |
| Foss, AJ | 1 |
| Hungerford, JL | 1 |
| Hickson, ID | 1 |
| Cree, IA | 1 |
| Nagel, JD | 1 |
| Ghussen, F | 1 |
| Bode, U | 1 |
| White, RJ | 1 |
| Durr, FE | 1 |
| Matuszyk, J | 1 |
| Kuśnierczyk, H | 1 |
| Radzikowski, C | 1 |
| Arseneau, JC | 1 |
| Schoenfeld, DA | 1 |
| Borden, EC | 1 |
| Coates, AS | 1 |
| Bishop, J | 1 |
| Mann, GJ | 1 |
| Raghavan, D | 1 |
| Taylor, SA | 1 |
| Tranum, BT | 1 |
| Von Hoff, DD | 1 |
| Costanzi, JJ | 1 |
1 review available for mitoxantrone and Malignant Melanoma
| Article | Year |
|---|---|
Preclinical models in electrochemotherapy: the role of veterinary patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 2012 |
1 trial available for mitoxantrone and Malignant Melanoma
| Article | Year |
|---|---|
Isolated hyperthermic perfusion with mitoxantrone of melphalan in malignant melanoma of the limb.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chemotherapy, Cancer, Regiona | 1995 |
31 other studies available for mitoxantrone and Malignant Melanoma
| Article | Year |
|---|---|
Structural modification study of bis(substituted aminoalkylamino)anthraquinones. An evaluation of the relationship of the [2-[(2-hydroxyethyl)amino]ethyl]amino side chain with antineoplastic activity.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Colonic Neoplasms; Leukemia L1210; Leukemia, Experim | 1979 |
Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Leukemia, Experimental; Melanoma; Mice; Neoplasms, E | 1978 |
Structural modification study of mitoxantrone (DHAQ). Chloro-substituted mono- and bis[(aminoalkyl)amino]anthraquinones.
Topics: Animals; Anthraquinones; Leukemia L1210; Leukemia P388; Melanoma; Mitoxantrone; Structure-Activity R | 1987 |
Cannabidiol Interacts Antagonistically with Cisplatin and Additively with Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Cannabidiol; Cell Line; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Comparison of the Anticancer Effects of Arvanil and Olvanil When Combined with Cisplatin and Mitoxantrone in Various Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Humans; Melanoma; Mitoxantrone | 2022 |
Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cisplatin; Docetaxel; Humans; Melanoma; Melanoma | 2022 |
Exostosin 1 Knockdown Induces Chemoresistance in MV3 Melanoma Cells by Upregulating JNK and MEK/ERK Signaling.
Topics: Antineoplastic Agents; Doxorubicin; Drug Resistance, Neoplasm; Heparan Sulfate Proteoglycans; Humans | 2023 |
Synergy, Additivity and Antagonism between Esculetin and Six Commonly Used Chemotherapeutics in Various Malignant Melanoma Cell Lines-An Isobolographic Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cisplatin; Cytostatic A | 2023 |
Daphnetin, a Coumarin with Anticancer Potential against Human Melanoma: In Vitro Study of Its Effective Combination with Selected Cytostatic Drugs.
Topics: Cisplatin; Coumarins; Cytostatic Agents; Docetaxel; Epirubicin; Humans; Melanoma; Melanoma, Cutaneou | 2023 |
ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.
Topics: Activating Transcription Factor 3; Adenosine A1 Receptor Antagonists; Adult; Aged; Animals; Antineop | 2020 |
Nanocarrier-Mediated Chemo-Immunotherapy Arrested Cancer Progression and Induced Tumor Dormancy in Desmoplastic Melanoma.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Progressio | 2018 |
Pegylated hollow gold-mitoxantrone nanoparticles combining photodynamic therapy and chemotherapy of cancer cells.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Drug Stability; | 2018 |
Utilizing photosensitizing and radiosensitizing properties of TiO
Topics: Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Drug; Fibrosarcoma; | 2019 |
Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies.
Topics: Anacardic Acids; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Di | 2014 |
Melanoma therapy with transdermal mitoxantrone cubic phases.
Topics: Administration, Cutaneous; Antineoplastic Agents; Glycerides; Humans; Immunohistochemistry; Melanoma | 2016 |
Preparation and characterization of injectable Mitoxantrone poly (lactic acid)/fullerene implants for in vivo chemo-photodynamic therapy.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Combined Modality Therapy; Drug Carriers; | 2015 |
Improved anti-melanoma effect of a transdermal mitoxantrone ethosome gel.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Gels; Male; Melanoma; Mice; Mice, Inbred | 2015 |
Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Humans; Melanoma; | 2013 |
Evaluation of the in vitro cytotoxicity of mitoxantrone following repeated freeze-thaw cycles.
Topics: Animals; Antineoplastic Agents; Dogs; Dose-Response Relationship, Drug; Drug Stability; Freezing; Me | 2002 |
[Preparation of mitoxantrone liposomes and study on its in vivo distribution in rats after transdermal delivery].
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Female; Liposomes; Melanoma; Microscopy, | 2006 |
Disposition of mitoxantrone in patients.
Topics: Adenocarcinoma; Anthraquinones; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Evaluation; Fe | 1983 |
Mitoxantrone in malignant melanoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Male; Melanoma; Middle Aged; | 1984 |
Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics.
Topics: Animals; Anthraquinones; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Resistance; Female | 1982 |
(R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Colonic | 1994 |
Relationship between expression of topoisomerase II isoforms and chemosensitivity in choroidal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic A | 2000 |
Clinical pharmacokinetics of mitoxantrone in hyperthermic, isolated perfusion of the leg.
Topics: Adult; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hyperthermia, Induced; Leg; Male; M | 1991 |
Development of mitoxantrone.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Cell Line; Chemistry, Pharmaceutical; Colonic Neopla | 1985 |
Biological evaluation of mitoxantrone dihydrochloride synthesized by a new method. II. Comparison of Now 85/34 and Novantrone (Lederle) acute toxicity and antitumor activity.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Leukemia, Experimental; Male; Mela | 1989 |
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Topics: Anthraquinones; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans | 1986 |
Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Topics: Aminoacridines; Amsacrine; Anthracenes; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Fema | 1986 |
Phase II trial of 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino 9,10-anthracenedione dihydrochloride)(NSC 301739, DHAD) in patients with metastatic malignant melanoma. A Southwest Oncology Group pilot.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Drug Evaluation; Female; Humans; Infusions, Pare | 1985 |